Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.